Research Documents Rapid Detection of Structural Variation in a Human Genome Using BioNano’s Irys System

BioNano Genomics, Inc., the leader in genome mapping, and BGI, the world’s largest genomics organization, highlight the publication of a peer-reviewed research article and its accompanying data* in GigaScience. This article describes the rapid detection of structural variation in a human genome using the high-throughput, cost-effective genome mapping technology of the Irys® System. Structural variations are known to play an important role in human genetic diversity and disease susceptibility. However, comprehensive, efficient and unbiased discovery of structural variations has previously not been possible through next generation sequencing (NGS) and DNA arrays with their inherent technology limitations.

Following NICE’s Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX Breast Cancer Test

Genomic Health, Inc. (Nasdaq: GHDX) recently announced that, as of April 1, 2015, the Oncotype DX® test will be available to eligible breast cancer patients through the National Health Service (NHS) in England as the only multi-gene breast cancer test recommended by the National Institute for Health and Care Excellence (NICE) for use as an option to assist in chemotherapy treatment decision-making.

PDI, Inc. Subsidiary Interpace Diagnostics Announces PancraGen™ Benefits Reinforced in Pivotal Study Published in Endoscopy

PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, recently announced the publication of results of the pivotal PancraGen™ multicenter clinical validation study in the February 2015 issue of Endoscopy. The study concluded that PancraGen (formerly PathFinderTG®-Pancreas) is 90% accurate at predicting benign and malignant disease in patients with pancreatic cysts, providing important insights into patients’ likelihood of pancreatic cancer. These results provide support for using PancraGen to provide more informed management decisions for patients with pancreatic cysts, including whether surgery or surveillance is the most appropriate approach.

Ancon Medical NBT Disease Screening Offers Benefits at All Levels

Whether it’s at remote locations in under-developed areas or the neighborhood clinic, more effective disease screening technology will improve the delivery, effectiveness, costs and results of health care at all levels.

West Cancer Center Designated a Center of Excellence by Caris Life Sciences and Joins the Caris Centers of Excellence for Precision Medicine Network

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, recently announced the designation of West Cancer Center, a leader in oncology research and comprehensive cancer care located in Memphis, Tenn., as a center of excellence site in the Caris Centers of Excellence for Precision Medicine Network(TM) (Network). Additionally, Lee S. Schwartzberg, M.D., Medical Director of West Cancer Center, has been appointed Vice Chairman of the Network to help guide the development of standards for tumor profiling, design tumor profiling research protocols, and foster a collaborative environment for sharing best-practices and profiling implementation strategies for Network members.